Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Otorhinolaryngology

  Free Subscription


Articles published in Oral Oncol

Retrieve available abstracts of 394 articles:
HTML format



Single Articles


    August 2022
  1. DONA MG, Rollo F, Pichi B, Moretto S, et al
    Updates on Human Papillomavirus-driven oropharyngeal squamous cell carcinomas in a southern European country.
    Oral Oncol. 2022;131:105947.
    PubMed    


    July 2022
  2. DE VRIES J, Poelman A, Sidorenkov G, Festen S, et al
    The association of frailty and outcomes of geriatric assessment with acute radiation-induced toxicity in patients with head and neck cancer.
    Oral Oncol. 2022;130:105933.
    PubMed     Abstract available


  3. RIBEIRO MFA, Oliveira MCM, Leite AC, Bruzinga FFB, et al
    Assessment of screening programs as a strategy for early detection of oral cancer: a systematic review.
    Oral Oncol. 2022;130:105936.
    PubMed     Abstract available


  4. TANG R, Mao S, Liu S, Li Z, et al
    Types of endoscopic surgical approaches for benign parapharyngeal space tumors.
    Oral Oncol. 2022;130:105875.
    PubMed    


    June 2022
  5. MISRA SR, Das R
    Central oral medicine repository: A proposal to speed up the diagnostic process for oral potentially malignant disorders and oral carcinoma!
    Oral Oncol. 2022;132:105998.
    PubMed    


  6. BALACHANDER K, Paramasivam A
    Anti-PD-1 agent: A promising immunotherapy drug for oral cancer?
    Oral Oncol. 2022;132:105997.
    PubMed    


  7. BABU S, Krishnan M, Priya Veeraraghavan V, Jayaraman S, et al
    Role of salivary miRNAs in the diagnosis and prognosis of head and neck squamous cell carcinoma.
    Oral Oncol. 2022;132:105993.
    PubMed    


  8. ALESSANDRINI L, Ferrari M, Taboni S, Sbaraglia M, et al
    Tumor-stroma ratio, neoangiogenesis and prognosis in laryngeal carcinoma. A pilot study on preoperative biopsies and matched surgical specimens.
    Oral Oncol. 2022;132:105982.
    PubMed     Abstract available


  9. SHREE HARINI K, Ezhilarasan D, Lakshmi T
    Novel fibroblast growth factor receptor inhibitors: Potential therapeutic approach in oral cancer treatment.
    Oral Oncol. 2022;132:105983.
    PubMed    


  10. REVATHI D, Dhanraj G, Ashok V
    Immune check point inhibitors: A promising therapeutic approach in oral cancer.
    Oral Oncol. 2022;132:105977.
    PubMed    


  11. SEKARAN S, Pitchaiah S, Ganapathy D
    Can miR-21 be considered as a potential biomarker and a therapeutic target in oral cancer?
    Oral Oncol. 2022;131:105973.
    PubMed    


  12. ZONG J, Ji P, Lin C, Zhang R, et al
    Plasma Epstein-Barr viral DNA load after completion of two cycles of induction chemotherapy predicts outcomes for patients with advanced-stage nasopharyngeal carcinoma.
    Oral Oncol. 2022;131:105972.
    PubMed     Abstract available


  13. BALACHANDER K, Paramasivam A
    Ferroptosis: An emerging therapeutic target for oral cancer.
    Oral Oncol. 2022;131:105970.
    PubMed    


  14. GANAPATHY D, Sekaran S, Pitchaiah S
    Is prognostic monitoring of high-risk populations at risk for oral cancer necessary after infection with COVID-19?
    Oral Oncol. 2022;131:105968.
    PubMed    


  15. LUO HD, Xia FJ, Wu JH, Yi B, et al
    Efficacy of chemoradiotherapy in survival of stage nasopharyngeal carcinoma and establishment of a prognostic model.
    Oral Oncol. 2022;131:105927.
    PubMed     Abstract available


  16. SHREE HARINI K, Ezhilarasan D, Lakshmi T
    Patient derived tumour organoids: An emerging strategy in oral cancer research and therapeutics.
    Oral Oncol. 2022;131:105954.
    PubMed    


  17. VARGHESE BT, Nair SP, Janardhan D
    Transglottic intralaryngeal papillary thyroid carcinoma.
    Oral Oncol. 2022;131:105935.
    PubMed     Abstract available


  18. YANG Z, Liao J, Schumaker L, Carter-Cooper B, et al
    Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma.
    Oral Oncol. 2022;131:105939.
    PubMed     Abstract available


  19. SHREE HARINI K, Ezhilarasan D
    Promising autophagy inhibitors: Therapeutic implications in oral cancer.
    Oral Oncol. 2022;131:105948.
    PubMed    


  20. DE FELICE F
    FLASH radiotherapy in head and neck cancer: Myth or reality?
    Oral Oncol. 2022;131:105953.
    PubMed    


  21. FERRELI F, Pirola F, Di Santo D, De Virgilio A, et al
    A critical analysis of the classifications of squamous cell carcinoma of the nasal vestibule.
    Oral Oncol. 2022;129:105880.
    PubMed    


    May 2022
  22. JAYARAMAN S, Pazhani J, PriyaVeeraraghavan V, Raj AT, et al
    PCNA and Ki67: Prognostic proliferation markers for oral cancer.
    Oral Oncol. 2022;130:105943.
    PubMed    


  23. BALACHANDER K, Paramasivam A
    Selective autophagy as a potential therapeutic target for oral cancer.
    Oral Oncol. 2022;130:105934.
    PubMed    


  24. PATIL VM, Kolkur M, Kumar Chinthala S, Waratkar G, et al
    Long term toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin-ineligible head and neck cancer patients.
    Oral Oncol. 2022;130:105908.
    PubMed    


  25. UEDA Y, Okano S, Enokida T, Fujisawa T, et al
    Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study.
    Oral Oncol. 2022;130:105932.
    PubMed     Abstract available


  26. WARNER L, O'Hara JT, Lin DJ, Oozeer N, et al
    Transoral robotic surgery and neck dissection alone for head and neck squamous cell carcinoma: Influence of resection margins on oncological outcomes.
    Oral Oncol. 2022;130:105909.
    PubMed     Abstract available


  27. VARGHESE BT, Shivanesan P
    Anatomical distortion of the right recurrent laryngeal nerve in level 7 neck dissection.
    Oral Oncol. 2022;130:105929.
    PubMed    


  28. SMILINE GIRIJA AS
    Natural "epidrugs" and the need of basket trials in the treatment of oral cancer in India.
    Oral Oncol. 2022;130:105931.
    PubMed    


  29. SHIAO JC, Holt D, Ladbury C, Gao D, et al
    The role of concomitant chemoradiotherapy versus radiation alone in T1-3N0 HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;130:105907.
    PubMed     Abstract available


  30. LOW SK, Reed CT, Millo C, Turkbey EB, et al
    Cecal mass: An unusual site of metastasis from HPV-associated oropharyngeal cancer.
    Oral Oncol. 2022;130:105928.
    PubMed    


  31. PARAMASIVAM A
    Plasma circulating tumor DNA as a molecular marker for oral cancer.
    Oral Oncol. 2022;130:105926.
    PubMed    


  32. SELVARAJ J, Yasothkumar D, Vishnu Priya V, Raj AT, et al
    Development and tumorigenic potential of TP53: A therapeutic target for head and neck squamous cell carcinoma.
    Oral Oncol. 2022;130:105922.
    PubMed    


  33. YANG X, Song H, Ji T, Du G, et al
    The implications of gene mutations in salivary DNA for noninvasive diagnosis of head and neck cancer with a focus on oral cancer.
    Oral Oncol. 2022;130:105924.
    PubMed     Abstract available


  34. FORNER D, Mok F, Verma N, Karam I, et al
    Placement technique impacts gastrostomy tube-related complications amongst head and neck cancer patients.
    Oral Oncol. 2022;130:105903.
    PubMed     Abstract available


  35. PAZHANI J, Jayaraman S, Veeraraghavan VP, Somasundaram DB, et al
    Targeting cancer associated fibroblasts - A TGF-beta based immunotherapy for head and neck squamous cell carcinoma.
    Oral Oncol. 2022;130:105899.
    PubMed    


  36. JIANG Y, Yang S, Qi Y
    Comment on: The prognostic value of radiologic extranodal extension in nasopharyngeal carcinoma: Systematic review and meta-analysis.
    Oral Oncol. 2022;130:105872.
    PubMed    


  37. MADY LJ, Baddour K, Hodges JC, Magana LC, et al
    Corrigendum to "The impact of frailty on mortality in non-surgical head and neck cancer treatment: Shifting the clinical paradigm" [Oral Oncol. 126 (2022) 105766].
    Oral Oncol. 2022 May 2:105882. doi: 10.1016/j.oraloncology.2022.105882.
    PubMed    


  38. SWARTZ JE, Smits HJG, Philippens MEP, de Bree R, et al
    Correlation and colocalization of HIF-1alpha and pimonidazole staining for hypoxia in laryngeal squamous cell carcinomas: A digital, single-cell-based analysis.
    Oral Oncol. 2022;128:105862.
    PubMed     Abstract available


  39. YEOM S, Jung EK, Lee DH, Lee JK, et al
    Clinical features and recurrence factors of benign neoplasms of the tongue base.
    Oral Oncol. 2022;128:105866.
    PubMed     Abstract available


  40. MULLER RG, Hamill CS, Vu B, Thuener J, et al
    Impact of AJCC 8th edition staging system and definitive treatment choice on the prognosis of complete responders with p16+ and p16- oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2022;128:105861.
    PubMed     Abstract available


    April 2022
  41. GALLOGLY JA JR, Weber AK, Mazul AL, Brinkmeier JV, et al
    Inferior outcomes associated with emergency department presentation for head and neck cancer surgery.
    Oral Oncol. 2022;129:105894.
    PubMed     Abstract available


  42. SHE L, Tian K, Han J, Zuo W, et al
    Pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy to treat recurrent or metastatic head and neck squamous cell carcinoma: An updated KEYNOTE-048 based cost-effectiveness analysis.
    Oral Oncol. 2022;129:105871.
    PubMed     Abstract available


  43. KATO A, Matsuda Y, Morioka R, Okui T, et al
    Discrepancy between subjective and objective postoperative oral dysfunction assessment after oral cancer treatment: A single-center cross-sectional study.
    Oral Oncol. 2022;129:105879.
    PubMed     Abstract available


  44. HAIST C, Poschinski Z, Bister A, Hoffmann MJ, et al
    Engineering a single-chain variable fragment of cetuximab for CAR T-cell therapy against head and neck squamous cell carcinomas.
    Oral Oncol. 2022;129:105867.
    PubMed     Abstract available


  45. SEKAR D, Panagal M, Manimaran D, Ahmad N, et al
    miR-185 and its anti-miR as a biomarker and therapeutic target for oral cancer.
    Oral Oncol. 2022;129:105873.
    PubMed    


  46. LIU T, Ma L, Song L, Yan B, et al
    CENPM upregulation by E5 oncoprotein of human papillomavirus promotes radiosensitivity in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;129:105858.
    PubMed     Abstract available


  47. NERALLA M, Senthilnthan P, Kubendiran D, Nandan A, et al
    Dry needle therapy for post operative shoulder dysfunction in oral cancer patients.
    Oral Oncol. 2022;128:105865.
    PubMed    


  48. PETRELLI F, Trevisan F, Ghidini A, Capriotti V, et al
    Comparison of platinum-based regimens in combination with radiotherapy for head and neck cancers: A network meta-analysis.
    Oral Oncol. 2022;128:105864.
    PubMed    


  49. ZHOU S, Chan C, Rulach R, Dyab H, et al
    Long term survival in patients with human papillomavirus-positive oropharyngeal cancer and equivocal response on 12-week PET-CT is not compromised by the omission of neck dissection.
    Oral Oncol. 2022;128:105870.
    PubMed     Abstract available


  50. YANG ZC, Nie ZQ, Chen QY, Du CC, et al
    Cost-Effectiveness analysis of combining plasma Epstein-Barr virus DNA testing and different surveillance imaging modalities for nasopharyngeal carcinoma patients in first remission.
    Oral Oncol. 2022;128:105851.
    PubMed     Abstract available


  51. FENG G, Feng H, Qi Y, Wang T, et al
    Interaction analysis between germline genetic variants and somatic mutations in head and neck cancer.
    Oral Oncol. 2022;128:105859.
    PubMed     Abstract available


  52. CHEN Y, Zheng X, Lin J, Gao X, et al
    A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients.
    Oral Oncol. 2022;128:105860.
    PubMed     Abstract available


  53. TIAN K, Han J, Wang Z, Chen J, et al
    Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis.
    Oral Oncol. 2022;128:105842.
    PubMed     Abstract available


  54. BALACHANDER K, Roy A, Priyadharsini JV, Murugan S, et al
    Mitochondrial DNA in circulating exosomes: A novel biomarker and potential therapeutic target for oral cancer.
    Oral Oncol. 2022;128:105857.
    PubMed    


  55. DE LA COUR CD, Munk C, Aalborg GL, Kjaer SK, et al
    Base of tongue/tonsillar and laryngeal cancer in Denmark 1994-2018: Temporal trends in incidence according to education and age.
    Oral Oncol. 2022;128:105832.
    PubMed     Abstract available


  56. BANERJEE A, Misra SR, Roy B, Singh S, et al
    Central oral histopathology registry (COHR) - A proposal promising hope for oral cancer and oral pathology research.
    Oral Oncol. 2022;128:105856.
    PubMed    


  57. SEKAR D, Murthykumar K, Ganapathy D
    miR-206 and its mimics: A predictive biomarker and therapeutic molecule in the treatment of oral cancer.
    Oral Oncol. 2022;128:105849.
    PubMed    


  58. RISCHIN D, Harrington KJ, Greil R, Soulieres D, et al
    Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
    Oral Oncol. 2022;128:105815.
    PubMed     Abstract available


  59. TANS L, Al-Mamgani A, Kwa SLS, Elbers JBW, et al
    Single vocal cord irradiation for early-stage glottic cancer: Excellent local control and favorable toxicity profile.
    Oral Oncol. 2022;127:105782.
    PubMed     Abstract available


  60. DODDAWAD VG, Premalatha BR, Sreeshyla HS, Nitin P, et al
    Classification staging systems on clinical and radiographic features of inverted sinonasal papilloma: A case report.
    Oral Oncol. 2022;127:105768.
    PubMed     Abstract available


    March 2022
  61. PATIL V, Noronha V, Joshi A, Menon N, et al
    RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation.
    Oral Oncol. 2022;128:105816.
    PubMed     Abstract available


  62. CHANG CT, Liu SP, Muo CH, Liao YF, et al
    The impact of dental therapy timelines and irradiation dosages on osteoradionecrosis in oral cancer patients: A population-based cohort study.
    Oral Oncol. 2022;128:105827.
    PubMed     Abstract available


  63. HSIEH MC, Wang CC, Yang CC, Lien CF, et al
    The role of induction chemotherapy in patients with locally advanced head and neck squamous cell carcinoma: A nationwide population-based matched study.
    Oral Oncol. 2022;128:105848.
    PubMed     Abstract available


  64. YANG X, Xu X, Zhang C, Ji T, et al
    The diagnostic value and prospects of gene mutations in circulating tumor DNA for head and neck cancer monitoring.
    Oral Oncol. 2022;128:105846.
    PubMed     Abstract available


  65. RANJAN MISRA S, Das R
    Tele-screening for early detection of oral cancer during the COVID-19 pandemic era: Diagnostic pitfalls and potential misinterpretations!
    Oral Oncol. 2022;128:105845.
    PubMed    


  66. MATTOX AK, D'Souza G, Khan Z, Allen H, et al
    Comparison of next generation sequencing, droplet digital PCR, and quantitative real-time PCR for the earlier detection and quantification of HPV in HPV-positive oropharyngeal cancer.
    Oral Oncol. 2022;128:105805.
    PubMed     Abstract available


  67. BALACHANDER K, Paramasivam A
    Cell-free mitochondrial DNA as a novel non-invasive biomarker for oral cancer.
    Oral Oncol. 2022;127:105825.
    PubMed    


  68. YAMAGUMA Y, Kaneuji T, Shirouzu S, Fukui T, et al
    Combination therapy of Mohs paste and chemotherapy improved metastatic oral cancer to the precordium skin and bilateral axillary lymph nodes: A case report.
    Oral Oncol. 2022;127:105817.
    PubMed     Abstract available


  69. VILLARD A, Breuskin I, Casiraghi O, Asmandar S, et al
    Confocal laser endomicroscopy and confocal microscopy for head and neck cancer imaging: Recent updates and future perspectives.
    Oral Oncol. 2022;127:105826.
    PubMed     Abstract available


  70. PATIL V, Alone M, Rai R, Noronha V, et al
    Safety and efficacy of pembrolizumab with chemotherapy in locally advanced head and neck cancers.
    Oral Oncol. 2022;127:105824.
    PubMed    


  71. DE LUCA P, Di Stadio A, Tassone D, de Campora L, et al
    Large cervical mass and head and neck cancer. First report of ectopic papillary adenoma of the lung.
    Oral Oncol. 2022;127:105823.
    PubMed     Abstract available


  72. DEVARAJA K, Kabekkodu SP
    Oral microbiome; a potential game-changer in the management of oral cancer?
    Oral Oncol. 2022;127:105822.
    PubMed    


  73. BONETTI VALENTE V, Mantovan Mazzon B, Urbano Collado F, Conrado Neto S, et al
    Clinicopathological and prognostic profile of non-smoking and non-drinking head and neck cancer patients: a population-based comparative study.
    Oral Oncol. 2022;127:105799.
    PubMed     Abstract available


  74. SHETH S, Gilbert J, Deal AM, Chera B, et al
    Mature follow up of induction chemotherapy with carboplatin, nab-paclitaxel, cetuximab in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;127:105807.
    PubMed    


  75. VALERO C, Yuan A, Zanoni DK, Lei E, et al
    Young non-smokers with oral cancer: What are we missing and why?
    Oral Oncol. 2022;127:105803.
    PubMed     Abstract available


  76. ELUMALAI P, Ezhilarasan D, Lakshmi T
    Targeting head and neck cancer epigenetics with CRISPR-dCas9: An emerging therapeutic approach.
    Oral Oncol. 2022;127:105801.
    PubMed    


  77. GLAZAR DJ, Johnson M, Farinhas J, Steuer CE, et al
    Early response dynamics predict treatment failure in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumab.
    Oral Oncol. 2022;127:105787.
    PubMed     Abstract available


  78. ROUTILA J, Qiao X, Weltner J, Rantala JK, et al
    Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma.
    Oral Oncol. 2022;127:105772.
    PubMed     Abstract available


  79. BRODY RM, Shimunov D, Cohen RB, Lin A, et al
    A benchmark for oncologic outcomes and model for lethal recurrence risk after transoral robotic resection of HPV-related oropharyngeal cancers.
    Oral Oncol. 2022;127:105798.
    PubMed     Abstract available


  80. GONCALVES JM, Scarini JF, Gondak R, Altemani A, et al
    Oral involvement of sinonasal undifferentiated carcinoma: A case report and immunohistochemical study of a challenging case.
    Oral Oncol. 2022;126:105779.
    PubMed     Abstract available


  81. SAKTHIVEL P, Raveendran S, Rajeshwari M
    Sinonasal small round blue cell tumors: What the clinician must know!
    Oral Oncol. 2022;126:105735.
    PubMed    


  82. PETRIDES GA, Dunn M, Charters E, Venchiarutti R, et al
    Health-related quality of life in maxillectomy patients undergoing dentoalveolar rehabilitation.
    Oral Oncol. 2022;126:105757.
    PubMed     Abstract available


    February 2022
  83. QURESHI HA, Zhu X, Yang GH, Steadele M, et al
    Impact of HPV status on immune responses in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;127:105774.
    PubMed     Abstract available


  84. BELGIOIA L, Becherini C, Bacigalupo A, Bonomo P, et al
    Chemo- immunotherapy and radiation in locally advanced head and neck cancer: Where do we stand?
    Oral Oncol. 2022;127:105773.
    PubMed     Abstract available


  85. DAGLINAMRATA, Lakshmi T, Rushabh D, Dineshkumar T, et al
    Telescreening as an alternate modality for early detection of oral cancer.
    Oral Oncol. 2022;127:105785.
    PubMed    


  86. HARING CT, Dermody SM, Yalamanchi P, Kang SY, et al
    The future of circulating tumor DNA as a biomarker in HPV related oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;126:105776.
    PubMed     Abstract available


  87. MICHMERHUIZEN NL, Heenan C, Wang J, Leonard E, et al
    Combined Pik3ca-H1047R and loss-of-function Notch1 alleles decrease survival time in a 4-nitroquinoline N-oxide-driven head and neck squamous cell carcinoma model.
    Oral Oncol. 2022;126:105770.
    PubMed    


  88. MADY LJ, Baddour K, Hodges JC, Magana LC, et al
    The impact of frailty on mortality in non-surgical head and neck cancer treatment: Shifting the clinical paradigm.
    Oral Oncol. 2022;126:105766.
    PubMed     Abstract available


  89. ZHANG S, Zhang W, Zhang J
    Comprehensive analysis of immune cell infiltration and significant genes in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;126:105755.
    PubMed     Abstract available


  90. LI JL, Hsieh TL, Ou MC, Lin FC, et al
    Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio during immune checkpoint inhibitor treatment in recurrent or metastatic head and neck squamous cell carcinoma patients.
    Oral Oncol. 2022;126:105729.
    PubMed    


  91. LENOCI D, Carenzo A, Cavalieri S, Pistore F, et al
    Biological properties of hypoxia-related gene expression models/signatures on clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity trials.
    Oral Oncol. 2022;126:105756.
    PubMed    


  92. CHAN SK, Lin C, Huang SH, Chau TC, et al
    Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma.
    Oral Oncol. 2022;126:105736.
    PubMed     Abstract available


  93. SILVERMAN DA, Parikh AS, Liu K, Zhan KY, et al
    Predictors of survival following carotid blowout syndrome.
    Oral Oncol. 2022;125:105723.
    PubMed     Abstract available


  94. CHIN O, Alshafai L, O'Sullivan B, Su J, et al
    Inter-rater concordance and operating definitions of radiologic nodal feature assessment in human papillomavirus-positive oropharyngeal carcinoma.
    Oral Oncol. 2022;125:105716.
    PubMed     Abstract available


  95. CHEN TC, Wang C, Su LY, Lin MC, et al
    Impact of invasion into cervical esophagus for patients with hypopharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;125:105683.
    PubMed     Abstract available


    January 2022
  96. SENGUPTA N, Sarode SC, Sarode GS, Ghone U, et al
    Scarcity of publicly available oral cancer image datasets for machine learning research.
    Oral Oncol. 2022;126:105737.
    PubMed     Abstract available


  97. JONAS H, Simnica D, Bussmann L, Zech H, et al
    Early relapse detection by monitoring of circulating cell-free DNA in patients with localized head and neck squamous cell carcinoma: A subgroup analysis of the multicenter randomized clinical trial IMSTAR-HN.
    Oral Oncol. 2022;126:105733.
    PubMed    


  98. SEKAR D
    Inhibition of OSCC derived ExomiRs and its therapeutic applications in oral cancer.
    Oral Oncol. 2022;126:105747.
    PubMed    


  99. FERRAZZO KL
    Regarding: "Clinical practice guidelines for dental management prior to radiation for head and neck cancer".
    Oral Oncol. 2022;126:105731.
    PubMed    


  100. WARD MC, Miller JA, Walker GV, Moeller BJ, et al
    The economic impact of circulating tumor-tissue modified HPV DNA for the post-treatment surveillance of HPV-driven oropharyngeal cancer: A simulation.
    Oral Oncol. 2022;126:105721.
    PubMed     Abstract available


  101. LIU X, Li WF, Ding C, Chen L, et al
    Differential benefit of induction chemotherapy according to body mass index in nasopharyngeal carcinoma - Pooled analysis of two randomized trials.
    Oral Oncol. 2022;125:105718.
    PubMed     Abstract available


  102. K AP, Selvakumar SC, Selvaraj J, Mony U, et al
    Reviewing the potential application of miR-21 inhibitors in oral cancer therapeutics.
    Oral Oncol. 2022;125:105713.
    PubMed    


  103. ECONOMOPOULOU P, Kotsantis I, Psyrri A
    Radiotherapy and immunotherapy combination in head and neck cancer: Does current failure qualify as an ending or is it a key to future success?
    Oral Oncol. 2022 Jan 13:105717. doi: 10.1016/j.oraloncology.2022.105717.
    PubMed    


  104. CARDIN GB, Bernard M, Bourbonnais J, Bahig H, et al
    The rs6942067 genotype is associated with a worse overall survival in young or non-smoking HPV-negative patients with positive nodal status in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;125:105696.
    PubMed    


  105. GILLIGAN G, Piemonte E, Lazos J, Panico R, et al
    Chronic wounds of traumatic origin and oral cancer arising de novo: A potential association?
    Oral Oncol. 2022;125:105711.
    PubMed    


  106. PATIL V, Ghandade N, Noronha V, Menon N, et al
    Hypomagnesemia in patients with locally advanced head and neck cancer treated weekly cisplatin-incidence and impact on outcomes.
    Oral Oncol. 2022;125:105709.
    PubMed    


  107. VIITASALO S, Karhemo PR, Vaananen J, Ilmarinen T, et al
    Exome sequencing reveals candidate mutations implicated in sinonasal carcinoma and malignant transformation of sinonasal inverted papilloma.
    Oral Oncol. 2022;124:105663.
    PubMed     Abstract available


  108. SAKTHIVEL P, Thakar A, Fernandez-Fernandez MM, Panda S, et al
    TransOral UltraSonic surgery (TOUSS) for oral cavity, oropharyngeal and supraglottic malignancy: A prospective study of feasibility, safety, margins, functional and survival outcomes.
    Oral Oncol. 2022;124:105643.
    PubMed     Abstract available


  109. LI MM, Mroz EA, Faquin WC, Lott-Limbach A, et al
    ERalpha: A biomarker and treatment target for oropharyngeal cancer?
    Oral Oncol. 2022;124:105637.
    PubMed    


  110. MALIK A, Panda S, Sakthivel P
    Treatment of early glottic carcinoma: Is it a paradox of choices?
    Oral Oncol. 2022;124:105516.
    PubMed    


  111. ZHANG L, Chen L, Xiao M, Xie X, et al
    Locally advanced undifferentiated sarcomatoid carcinoma of the right maxillary sinus with PDCD6-TERT fusion: A rare case report.
    Oral Oncol. 2022;124:105466.
    PubMed     Abstract available


    December 2021
  112. COHEN O, Brauer PR, Judson BL, Burtness BA, et al
    Guideline - Adherence in advanced stage head and neck cancer is associated with improved survival - A National study.
    Oral Oncol. 2021;125:105694.
    PubMed     Abstract available


  113. WANG J, Tian Y, Huang H, Huang D, et al
    The prognosis of HPV-associated metastatic pharyngeal patients by primary and distant site.
    Oral Oncol. 2021;125:105675.
    PubMed     Abstract available


  114. SUBASH A, Bylapudi B, Thakur S, Rao VUS, et al
    Oral cancer in India, a growing problem: Is limiting the exposure to avoidable risk factors the only way to reduce the disease burden?
    Oral Oncol. 2021;125:105677.
    PubMed     Abstract available


  115. MERCHANT YP, Mohan M, Shetty S, Bandemegal M, et al
    The submandibular gland in neck dissection: A necessary casualty or a hapless victim?
    Oral Oncol. 2021;125:105678.
    PubMed    


  116. HERNDON P, Jassal JS, Cramer JD
    Association between E-cigarette use and oral HPV-16 infection.
    Oral Oncol. 2021;125:105676.
    PubMed    


  117. DOU Y, Ma C, Wang K, Liu S, et al
    Dysbiotic tumor microbiota associates with head and neck squamous cell carcinoma outcomes.
    Oral Oncol. 2021;124:105657.
    PubMed     Abstract available


  118. NOJI R, Kano Y, Hirai H, Onishi I, et al
    MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma.
    Oral Oncol. 2021;124:105666.
    PubMed     Abstract available


  119. WEI LY, Lin HC, Tsai FC, Ko JY, et al
    Effects of Interleukin-6 on STAT3-regulated signaling in oral cancer and as a prognosticator of patient survival.
    Oral Oncol. 2021;124:105665.
    PubMed     Abstract available


  120. SARI SY, Yilmaz MT, Aktas BY, Aksoy S, et al
    Results of concurrent radiotherapy and immunotherapy in recurrent and metastatic head and neck cancer: A single-center experience.
    Oral Oncol. 2021;124:105658.
    PubMed     Abstract available


  121. CRAMER JD, Grauer J
    Modeling oral cancer screening in the United States population.
    Oral Oncol. 2021;124:105656.
    PubMed     Abstract available


  122. BIGELOW EO, Windon MJ, Fakhry C, Kiess AP, et al
    Development of a web-based, patient-centered decision aid for oropharyngeal cancer treatment.
    Oral Oncol. 2021;123:105618.
    PubMed     Abstract available


  123. BURNINGHAM K, Moore W, Moon D, Avkshtol V, et al
    Prognostic impact of matted lymphadenopathy in patients with oropharyngeal squamous cell carcinoma treated with definitive chemoradiotherapy.
    Oral Oncol. 2021;123:105623.
    PubMed     Abstract available


    November 2021
  124. GUPTA T, Maheshwari G, Kannan S, Nair S, et al
    Systematic review and meta-analysis of randomized controlled trials comparing elective neck dissection versus sentinel lymph node biopsy in early-stage clinically node-negative oral and/or oropharyngeal squamous cell carcinoma: Evidence-base for pract
    Oral Oncol. 2021;124:105642.
    PubMed     Abstract available


  125. CHAUHAN A, Kaur R, Ghoshal S, Chatterjee D, et al
    Potential prognostic and predictive role of baseline circulating tumor cells in head and neck squamous cell carcinoma.
    Oral Oncol. 2021;124:105636.
    PubMed    


  126. FUEREDER T, Minichsdorfer C, Mittlboeck M, Wagner C, et al
    Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study.
    Oral Oncol. 2021;124:105634.
    PubMed     Abstract available


  127. DENARO N, Merlano M, Garrone O
    In reply to immune desert in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment.
    Oral Oncol. 2021;124:105640.
    PubMed    


  128. THADURI A, Dungala D, Panuganti A, Majumdar KS, et al
    Addressing the challenges of head and neck cancer care in India - A compelling need of the hour.
    Oral Oncol. 2021;124:105638.
    PubMed    


  129. MADHULAXMI M, Abhinav RP
    Protein changes of WNT signaling pathway in oral cancer.
    Oral Oncol. 2021;123:105624.
    PubMed    


  130. KOWALCHUK RO, Van Abel KM, Yin LX, Garcia J, et al
    Correlation between radiographic and pathologic lymph node involvement and extranodal extension via CT and PET in HPV-associated oropharyngeal cancer.
    Oral Oncol. 2021;123:105625.
    PubMed     Abstract available


  131. GAU M, Fonseca A, Ozsahin M, Fayette J, et al
    Prognostic impact of extranodal extension in resected head and neck squamous cell carcinomas in the era of postoperative chemoradiation: A retrospective monocentric study.
    Oral Oncol. 2021;123:105605.
    PubMed     Abstract available


  132. MISHRA S, Subash A, Rao VUS, Thakur S, et al
    Role of neoadjuvant chemotherapy in head and neck cancer management: A case for exploring diverse treatment strategies for evaluating long-term efficacy.
    Oral Oncol. 2021;123:105594.
    PubMed    


  133. GOLUSINSKI P, Corry J, Poorten VV, Simo R, et al
    De-escalation studies in HPV-positive oropharyngeal cancer: How should we proceed?
    Oral Oncol. 2021;123:105620.
    PubMed     Abstract available


  134. WATSON E, Dorna Mojdami Z, Oladega A, Hope A, et al
    Clinical practice guidelines for dental management prior to radiation for head and neck cancer.
    Oral Oncol. 2021;123:105604.
    PubMed     Abstract available


  135. BRIL SI, Chargi N, Wendrich AW, Wegner I, et al
    Validation of skeletal muscle mass assessment at the level of the third cervical vertebra in patients with head and neck cancer.
    Oral Oncol. 2021;123:105617.
    PubMed     Abstract available


  136. WANG Y, Gao Y, Yuan L, Zhang J, et al
    Psychological needs and associated factors among perioperative patients with oral cancer.
    Oral Oncol. 2021;123:105615.
    PubMed    


  137. GRONLUND MP, Jakobsen KK, Mirian C, Gronhoj C, et al
    Nasopharyngeal malignancies in Denmark diagnosed from 1980 to 2014.
    Oral Oncol. 2021;122:105583.
    PubMed     Abstract available


  138. YU J, Tsay C, Sasaki C, Son YH, et al
    Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs.
    Oral Oncol. 2021;122:105585.
    PubMed     Abstract available


  139. SEE A, Chu C, Kiong KL, Teo C, et al
    Surgical salvage of recurrent nasopharyngeal cancer- a multi-institutional review.
    Oral Oncol. 2021;122:105556.
    PubMed    


  140. SAKTHIVEL P, Ramanikanth TV, Thakar A, Singh CA, et al
    TransOral UltraSonic Surgery (TOUSS) assisted supraglottic laryngectomy: Expanding the spectrum of endoscopic head and neck surgeries.
    Oral Oncol. 2021;122:105562.
    PubMed    


  141. THAKAR A, Sakthivel P, Sikka K
    TransOral UltraSonic Surgery (TOUSS) and TransOral Laser (TOL) assisted supraglottic laryngectomy (TOUSS-TOL-SGL): Improvising techniques within the transoral corridor.
    Oral Oncol. 2021;122:105573.
    PubMed    


  142. LIN N, Gao J, Wang H, Zhang H, et al
    Diagnostic value of indocyanine green for sentinel lymph node mapping and lymph node metastasis in oral/oropharyngeal carcinoma.
    Oral Oncol. 2021;122:105563.
    PubMed     Abstract available


  143. RE M, Tomasetti M, Monaco F, Amati M, et al
    NGS-based miRNome identifies miR-449 cluster as marker of malignant transformation of sinonasal inverted papilloma.
    Oral Oncol. 2021;122:105554.
    PubMed     Abstract available


  144. MCDOWELL L, Casswell G, Bressel M, Drosdowsky A, et al
    Symptom burden, quality of life, functioning and emotional distress in survivors of human papillomavirus associated oropharyngeal cancer: An Australian cohort.
    Oral Oncol. 2021;122:105560.
    PubMed     Abstract available


  145. MIN PARK Y, Yol Lim J, Woo Koh Y, Kim SH, et al
    Prediction of treatment outcome using MRI radiomics and machine learning in oropharyngeal cancer patients after surgical treatment.
    Oral Oncol. 2021;122:105559.
    PubMed     Abstract available


    October 2021
  146. GEORGE A, Saseendran A, Joseph ST, Gopal KR, et al
    Submandibular gland - The victim of neck dissection.
    Oral Oncol. 2021;123:105591.
    PubMed    


  147. CABEZAS-CAMARERO S, Alonso-Ovies A, Merino-Menendez S, Cabrera-Martin MN, et al
    Major pathological response and durable locoregional control after neoadjuvant pembrolizumab-carboplatin-paclitaxel in head and neck cancer.
    Oral Oncol. 2021;123:105589.
    PubMed     Abstract available


  148. BRUIJNEN CP, de Groot LGR, Vondeling AM, de Bree R, et al
    Functional decline after surgery in older patients with head and neck cancer.
    Oral Oncol. 2021;123:105584.
    PubMed     Abstract available


  149. PUTHIYOTTIL IV, Subash A, Thakur S, Rao VUS, et al
    Elective neck dissection versus sentinel node biopsy in early oral cavity cancer - Are we ready for transition?
    Oral Oncol. 2021;123:105597.
    PubMed    


  150. SHINN JR, Carey RM, Mady LJ, Shimunov D, et al
    Sex-based differences in outcomes among surgically treated patients with HPV-related oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2021;123:105570.
    PubMed     Abstract available


  151. JOSE MARTELLI A, Assis Machado R, Medeiros Pereira W, Balduino Guimaraes Santos F, et al
    Revaluation of the treatment of head and neck cancer in Brazil during the COVID-19 pandemic - phase 2.
    Oral Oncol. 2021;123:105600.
    PubMed    


  152. YUWANATI M, Sarode SC, Gadbail A, Gondivkar S, et al
    Alcohol attributed Oral Cancer and Oral microbiome: Emerging yet neglected research domain.
    Oral Oncol. 2021;123:105596.
    PubMed    


  153. YU ST, Ge JN, Sun BH, Wei ZG, et al
    Lymph node yield in the initial central neck dissection (CND) associated with the risk of recurrence in papillary thyroid cancer: A reoperative CND cohort study.
    Oral Oncol. 2021;123:105567.
    PubMed     Abstract available


  154. SHU L, Wang D, Nannapaneni S, Sun Y, et al
    Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC).
    Oral Oncol. 2021;122:105546.
    PubMed     Abstract available


  155. MA D, Orner D, Ghaly MM, Parashar B, et al
    Automated health chats for symptom management of head and neck cancer patients undergoing radiation therapy.
    Oral Oncol. 2021;122:105551.
    PubMed     Abstract available


  156. ZHAO Y, Li WF, Li QJ, He SW, et al
    WIPI-1 inhibits metastasis and tumour growth via the WIPI-1-TRIM21 axis and MYC regulation in nasopharyngeal carcinoma.
    Oral Oncol. 2021;122:105576.
    PubMed     Abstract available


  157. ROSENBERG AJ, Agrawal N, Pearson A, Gooi Z, et al
    Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience.
    Oral Oncol. 2021;122:105566.
    PubMed     Abstract available


  158. TSENG WH, Li TH, Chiu HL, Yang TL, et al
    Long-term swallowing-related outcomes in oral cancer patients receiving proactive swallowing therapy.
    Oral Oncol. 2021;122:105569.
    PubMed     Abstract available


  159. BRIL SI, van Beers MA, Chargi N, Carrillo Minulina N, et al
    Skeletal muscle mass at C3 is a strong predictor for skeletal muscle mass at L3 in sarcopenic and non-sarcopenic patients with head and neck cancer.
    Oral Oncol. 2021;122:105558.
    PubMed    


  160. PENG H, Chen L, Mao YP, Tian L, et al
    Nomogram-aided individual induction chemotherapy regimen selection in advanced nasopharyngeal carcinoma.
    Oral Oncol. 2021;122:105555.
    PubMed     Abstract available


  161. CARNEVALE C, Pagan-Pomar A, Bianchi A, Sarria-Echegaray P, et al
    Right colonic interposition for severe pharyngoesophageal stricture in head and neck patients: A feasible rescue strategy after multiple failed reconstructive options.
    Oral Oncol. 2021;121:105481.
    PubMed     Abstract available


  162. HANS S, Chebib E, Chekkoury-Idrissi Y, Distinguin L, et al
    Surgical and oncological outcomes of transoral robotic total laryngectomy: A case series.
    Oral Oncol. 2021;121:105511.
    PubMed     Abstract available


  163. FINEGERSH A, Voora RS, Panuganti B, Faraji F, et al
    Robotic surgery may improve overall survival for T1 and T2 tumors of the hypopharynx: An NCDB cohort study.
    Oral Oncol. 2021;121:105440.
    PubMed     Abstract available


  164. AL MASALMEH N, Kukreja G, Zaiem F, Raza SN, et al
    p16 positive oropharyngeal small cell cancer: A case report.
    Oral Oncol. 2021;121:105391.
    PubMed     Abstract available


  165. HARING CT, Brummel C, Bhambhani C, Jewell B, et al
    Implementation of human papillomavirus circulating tumor DNA to identify recurrence during treatment de-escalation.
    Oral Oncol. 2021;121:105332.
    PubMed    


    September 2021
  166. CURY SS, Miranda PM, Marchi FA, Canto LMD, et al
    Germline variants in DNA repair genes are associated with young-onset head and neck cancer.
    Oral Oncol. 2021;122:105545.
    PubMed     Abstract available


  167. WANG BC
    Adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Finding the suitable population.
    Oral Oncol. 2021 Sep 28:105544. doi: 10.1016/j.oraloncology.2021.105544.
    PubMed    


  168. SARODE SC, Sarode GS, Sengupta N, Ghone U, et al
    Tobacco induced epithelial dysplasia at minor salivary gland excretory duct and oral cancer.
    Oral Oncol. 2021;122:105525.
    PubMed    


  169. MENON N, Patil V, Noronha V, Joshi A, et al
    Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone - Additional data from a phase 3 trial.
    Oral Oncol. 2021;122:105517.
    PubMed     Abstract available


  170. ZHU MY, Sun XS, Guo SS, Chen QY, et al
    Do all patients with locoregionally advanced nasopharyngeal carcinoma benefit from the maintenance chemotherapy using S-1/capecitabine?
    Oral Oncol. 2021;122:105539.
    PubMed     Abstract available


  171. ZHOU X, Xu T, Yang Y, Xing X, et al
    Survival impact of increasing time to IMRT initiation following induction chemotherapy in nasopharyngeal carcinoma: A propensity score-matched analysis.
    Oral Oncol. 2021;122:105506.
    PubMed     Abstract available


  172. KIONG KL, Bell D, Yao CM, Ferrarotto R, et al
    Multifocal regression and pathologic response predicts recurrence after neoadjuvant chemotherapy in head and neck squamous cell carcinoma.
    Oral Oncol. 2021;122:105520.
    PubMed     Abstract available


  173. AJAZ S, Muneer R, Siddiqa A, Ali Memon M, et al
    Association of specific single nucleotide variants (SNVs) in the promoter and 3'-Untranslated region of Vascular Endothelial growth factor (VEGF) gene with risk and higher tumour grade of head and neck cancers.
    Oral Oncol. 2021;122:105519.
    PubMed     Abstract available


  174. TSAI TY, Chou YC, Lu YA, Kang CJ, et al
    The prognostic value of radiologic extranodal extension in nasopharyngeal carcinoma: Systematic review and meta-analysis.
    Oral Oncol. 2021;122:105518.
    PubMed     Abstract available


  175. IDA S, Takahashi H, Kawabata-Iwakawa R, Mito I, et al
    Tissue-resident memory T cells correlate with the inflammatory tumor microenvironment and improved prognosis in head and neck squamous cell carcinoma.
    Oral Oncol. 2021;122:105508.
    PubMed     Abstract available


  176. SAKTHIVEL P, Malik A, Panda S, Dhiwakar M, et al
    8 "S" of obturators in Head and Neck Cancer Rehabilitation during COVID-19 pandemic.
    Oral Oncol. 2021 Sep 8:105523. doi: 10.1016/j.oraloncology.2021.105523.
    PubMed    


  177. MILLIET F, Bozec A, Schiappa R, Viotti J, et al
    Metachronous second primary neoplasia in oropharyngeal cancer patients: Impact of tumor HPV status. A GETTEC multicentric study.
    Oral Oncol. 2021;122:105503.
    PubMed     Abstract available


  178. VAN HINTE G, Sancak T, Weijs WLJ, Merkx MAW, et al
    Effect of elective neck dissection versus sentinel lymph node biopsy on shoulder morbidity and health-related quality of life in patients with oral cavity cancer: A longitudinal comparative cohort study.
    Oral Oncol. 2021;122:105510.
    PubMed     Abstract available


    August 2021
  179. WRIGHT CM, Lee DY, Shimunov D, Carmona R, et al
    Definitive tumor directed therapy confers a survival advantage for metachronous oligometastatic HPV-associated oropharyngeal cancer following trans-oral robotic surgery.
    Oral Oncol. 2021;121:105509.
    PubMed     Abstract available


  180. VERDONCK-DE LEEUW IM, Melissant H, Lissenberg-Witte BI, Baatenburg de Jong RJ, et al
    Associations between testosterone and patient reported sexual outcomes among male and female head and neck cancer patients before and six months after treatment: A pilot study.
    Oral Oncol. 2021;121:105505.
    PubMed     Abstract available


  181. SCHAIK JEV, Halmos GB, Witjes MJH, Plaat BEC, et al
    An overview of the current clinical status of optical imaging in head and neck cancer with a focus on Narrow Band imaging and fluorescence optical imaging.
    Oral Oncol. 2021;121:105504.
    PubMed     Abstract available


  182. MYATRA SN, Gupta S, D'Cruz AK, Rajanala V, et al
    Identification of patients for a delayed extubation strategy versus elective tracheostomy for postoperative airway management in major oral cancer surgery: A prospective observational study in seven hundred and twenty patients.
    Oral Oncol. 2021;121:105502.
    PubMed     Abstract available


  183. MIN Y, Xiang K, Feng Y, Chen H, et al
    Development and validation of a population-based model for predicting the regional lymph node metastasis in adolescent differentiated thyroid carcinoma.
    Oral Oncol. 2021;121:105507.
    PubMed     Abstract available


  184. YANG Q, Xia L, Lin M, Zhang MX, et al
    The impact of induction chemotherapy on long-term quality of life in patients with locoregionally advanced nasopharyngeal carcinoma: Outcomes from a randomised phase 3 trial.
    Oral Oncol. 2021;121:105494.
    PubMed     Abstract available


  185. HOCHFELDER CG, Mehta V, Kabarriti R, McGinn AP, et al
    Survival analysis of patients with advanced hypopharyngeal cancer comparing patients who received primary surgery to those who received chemoradiation: An analysis of the NCDB.
    Oral Oncol. 2021;121:105470.
    PubMed     Abstract available


  186. BUENO DE OLIVEIRA T, Camila Braun A, Ribaldo Nicolau U, Ali Abdallah E, et al
    Prognostic impact and potential predictive role of baseline circulating tumor cells in locally advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2021;121:105480.
    PubMed     Abstract available


  187. NAGPAL P, Pruthi DS, Pandey M, Yadav A, et al
    Impact of sarcopenia in locally advanced head and neck cancer treated with chemoradiation: An Indian tertiary care hospital experience.
    Oral Oncol. 2021;121:105483.
    PubMed     Abstract available


  188. JAWERT F, Nyman J, Olsson E, Adok C, et al
    Regular clinical follow-up of oral potentially malignant disorders results in improved survival for patients who develop oral cancer.
    Oral Oncol. 2021;121:105469.
    PubMed     Abstract available


  189. OHKOSHI A, Ishii R, Wakamori S, Nakayama Y, et al
    Serum selenium predicts achievement of full-dose cisplatin in concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: A prospective, observational study.
    Oral Oncol. 2021;121:105475.
    PubMed     Abstract available


  190. ENGEL MSD, van der Lans RJL, Jansen JC, Leemans CR, et al
    Management and outcome of middle ear adenomatous neuroendocrine tumours: A systematic review.
    Oral Oncol. 2021;121:105465.
    PubMed     Abstract available


  191. MCDOWELL L, Corry J
    Regarding "Comparing unilateral vs. bilateral neck management in lateralized oropharyngeal cancer between surgical and radiation oncologists: An international practice pattern survey" - Intra- and inter-specialty variability and the underutilisation o
    Oral Oncol. 2021;119:105248.
    PubMed    


  192. CHOI N, Kim Z, Song BH, Park W, et al
    Prediction of risk factors for pharyngo-cutaneous fistula after total laryngectomy using artificial intelligence.
    Oral Oncol. 2021;119:105357.
    PubMed     Abstract available


    July 2021
  193. MAO L, Xiao Y, Yang QC, Yang SC, et al
    TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
    Oral Oncol. 2021;121:105472.
    PubMed     Abstract available


  194. NIEUWENHUIS ER, Kolenaar B, van Bemmel AJM, Hof JJ, et al
    A complete magnetic sentinel lymph node biopsy procedure in oral cancer patients: A pilot study.
    Oral Oncol. 2021;121:105464.
    PubMed     Abstract available


  195. MATSUDA Y, Okui T, Karino M, Aoi N, et al
    Postoperative oral dysfunction following oral cancer resection and reconstruction: A preliminary cross-sectional study.
    Oral Oncol. 2021;121:105468.
    PubMed     Abstract available


  196. NAUTA IH, Klausch T, van de Ven PM, Hoebers FJP, et al
    The important role of cisplatin in the treatment of HPV-positive oropharyngeal cancer assessed by real-world data analysis.
    Oral Oncol. 2021;121:105454.
    PubMed     Abstract available


  197. DRAKE V, Bigelow E, Fakhry C, Windon M, et al
    Biologic and behavioral associations of estrogen receptor alpha positivity in head and neck squamous cell carcinoma.
    Oral Oncol. 2021;121:105461.
    PubMed     Abstract available


  198. KIM C, Martinez E, Kulich M, Swanson MS, et al
    Surgeon practice patterns in transoral robotic surgery for HPV-related oropharyngeal cancer.
    Oral Oncol. 2021;121:105460.
    PubMed     Abstract available


  199. XU Y, Chen M, Guo Q, Peng H, et al
    Percutaneous endoscopic gastrostomy can improve survival outcomes in patients with N3 nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy.
    Oral Oncol. 2021;121:105435.
    PubMed     Abstract available


  200. ALMANGUSH A, Alabi RO, Makitie AA, Leivo I, et al
    Machine learning in head and neck cancer: Importance of a web-based prognostic tool for improved decision making.
    Oral Oncol. 2021 Jul 12:105452. doi: 10.1016/j.oraloncology.2021.105452.
    PubMed    


  201. KOUKETSU A, Miyashita H, Kojima I, Sakamoto M, et al
    Comparison of different diagnostic imaging techniques for the detection of bone invasion in oral cancers.
    Oral Oncol. 2021;120:105453.
    PubMed     Abstract available


  202. MERCHANT YP, Kudpaje A, Rao VUS
    Extent of neck dissection in the N+ neck: Adjudicating a Conundrum!
    Oral Oncol. 2021 Jul 11:105441. doi: 10.1016/j.oraloncology.2021.105441.
    PubMed    


  203. IQBAL MS, Kovarik J, Patil R, Kelly CG, et al
    Are taxanes more effective than 5FU in combination chemotherapy for recurrent and metastatic head and neck cancer?
    Oral Oncol. 2021 Jul 9:105455. doi: 10.1016/j.oraloncology.2021.105455.
    PubMed    


  204. IMADUDDIN M, Sultania M, Vigneshwaran B, Muduly DK, et al
    Psychosocial Factors in an Oral Cancer Survivor Leading to Delay in Seeking Help.
    Oral Oncol. 2021 Jul 5:105438. doi: 10.1016/j.oraloncology.2021.105438.
    PubMed    


  205. WILKIE MD, Lancaster J, Roland NJ, Jones TM, et al
    Elective management of regional nodal basins in cutaneous squamous cell carcinoma of the head and neck: Controversies and contemporary perspectives.
    Oral Oncol. 2021;120:105432.
    PubMed     Abstract available


  206. KIM SY, Beer M, Tshering Vogel DW
    Imaging in head and neck cancers: Update for non-radiologist.
    Oral Oncol. 2021;120:105434.
    PubMed     Abstract available


  207. FARLOW JL, Brenner JC, Lei YL, Chinn SB, et al
    Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment.
    Oral Oncol. 2021;120:105420.
    PubMed     Abstract available


  208. DA COSTA REAR, da Silva Junior RG, Magalhaes LAN, Mendes JR, et al
    Locally advanced lymphoepithelial carcinoma of the larynx/hypopharynx: A case report.
    Oral Oncol. 2021;118:105373.
    PubMed     Abstract available


  209. TURNER MT, Stokes WA, Stokes CM, Hassid S, et al
    Airway and bleeding complications of transoral robotic supraglottic laryngectomy (TORS-SGL): A systematic review and meta-analysis.
    Oral Oncol. 2021;118:105301.
    PubMed    


  210. MCDOWELL L, Gough K, King M, Corry J, et al
    Patient-reported quality of life and symptom burden measures in human papillomavirus associated oropharyngeal cancer - A review of the literature and PRO methodology.
    Oral Oncol. 2021;118:105309.
    PubMed     Abstract available


  211. DHEERAJ K, Kumar R, Pinnaka LB
    6 "I" for endoscopic surgical management of early glottic squamous cell carcinomas.
    Oral Oncol. 2021;118:105308.
    PubMed    


    June 2021
  212. PATEL KB, Mroz EA, Faquin WC, Rocco JW, et al
    A combination of intra-tumor genetic heterogeneity, estrogen receptor alpha and human papillomavirus status predicts outcomes in head and neck squamous cell carcinoma following chemoradiotherapy.
    Oral Oncol. 2021;120:105421.
    PubMed     Abstract available


  213. RIBEIRO IP, Lopes T, Pedro N, Barroso L, et al
    Should sitting time be a treatment target in head and neck cancer patients receiving curative treatment?
    Oral Oncol. 2021 Jun 26:105418. doi: 10.1016/j.oraloncology.2021.105418.
    PubMed    


  214. DAHLSTROM KR, Anderson KS, Guo M, Kwon MC, et al
    Screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men: Initial report from the HOUSTON clinical trial.
    Oral Oncol. 2021;120:105397.
    PubMed     Abstract available


  215. YANG J, Wan SQ, Huang L, Zhong WJ, et al
    Analysis of hospitalization costs and length of stay for oral cancer patients undergoing surgery: Evidence from Hunan, China.
    Oral Oncol. 2021;119:105363.
    PubMed     Abstract available


  216. AMBRE S, Sultania M, Biswal S, Mitra S, et al
    Poorly differentiated "insular" thyroid carcinoma with solitary vascular mandibular metastasis - A rare histology and management.
    Oral Oncol. 2021 Jun 24:105416. doi: 10.1016/j.oraloncology.2021.105416.
    PubMed    


  217. ZHU MY, Wu HJ, Miao JJ, Di MP, et al
    Radiation-induced hypothyroidism in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy with or without chemotherapy: Development of a nomogram based on the equivalent dose.
    Oral Oncol. 2021;120:105378.
    PubMed     Abstract available


  218. LENZE NR, Farquhar DR, Sheth S, Zevallos JP, et al
    Prognostic impact of socioeconomic status compared to overall stage for HPV-negative head and neck squamous cell carcinoma.
    Oral Oncol. 2021;119:105377.
    PubMed     Abstract available


  219. LIEN MY, Wang TH, Hsieh CY, Tsai MH, et al
    Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
    Oral Oncol. 2021;119:105380.
    PubMed     Abstract available


  220. KAVARTHAPU A, Gurumoorthy K
    Linking chronic periodontitis and oral cancer: A review.
    Oral Oncol. 2021 Jun 14:105375. doi: 10.1016/j.oraloncology.2021.105375.
    PubMed     Abstract available


  221. MA C, Sheng S, Shen Y, Gao W, et al
    A comparative study on using superior thyroid artery perforator flaps versus traditional sternocleidomastoid myocutaneous flaps for reconstructions after oral cancer ablation: "New tricks for old dogs"?
    Oral Oncol. 2021 Jun 11:105374. doi: 10.1016/j.oraloncology.2021.105374.
    PubMed     Abstract available


  222. BRAS L, de Vries J, Festen S, Steenbakkers RJHM, et al
    Frailty and restrictions in geriatric domains are associated with surgical complications but not with radiation-induced acute toxicity in head and neck cancer patients: A prospective study.
    Oral Oncol. 2021;118:105329.
    PubMed     Abstract available


  223. KARABAJAKIAN A, Bouaoud J, Michon L, Kamal M, et al
    Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity.
    Oral Oncol. 2021;119:105368.
    PubMed     Abstract available


  224. XU J, Wang R, Wang T, Wang T, et al
    Targeted DNA profiling and the prevalence of NTRK aberrations in Chinese patients with head and neck cancer.
    Oral Oncol. 2021;119:105369.
    PubMed     Abstract available


  225. JIANG WN, Olson R
    Transoral surgery may be less cost effective than radiotherapy: In response to: Comparative cost analysis between definitive radiotherapy and transoral surgery for oropharyngeal squamous cell carcinoma: A SEER-medicare analysis.
    Oral Oncol. 2021;117:105178.
    PubMed    


  226. PARIKH AS, Kang SY
    Variation in elective treatment of the contralateral neck in oropharyngeal cancer.
    Oral Oncol. 2021;117:105186.
    PubMed    


  227. COMBES JD, Voisin N, Perie S, Malard O, et al
    History of tonsillectomy and risk of oropharyngeal cancer.
    Oral Oncol. 2021;117:105302.
    PubMed     Abstract available


  228. JANSEN F, Coupe VMH, Eerenstein SEJ, Cnossen IC, et al
    Cost-utility and cost-effectiveness of a guided self-help head and neck exercise program for patients treated with total laryngectomy: Results of a multi-center randomized controlled trial.
    Oral Oncol. 2021;117:105306.
    PubMed     Abstract available


  229. PATEL MR, Ottenstein L, Ryan M, Farrell A, et al
    TORS elective lingual tonsillectomy has less acute morbidity than therapeutic base of tongue TORS.
    Oral Oncol. 2021;117:105294.
    PubMed     Abstract available


    May 2021
  230. TECKIE S, Wotman M, Marziliano A, Orner D, et al
    Patterns of alcohol use among early head and neck cancer survivors: A cross-sectional survey study using the alcohol use disorders identification test (AUDIT).
    Oral Oncol. 2021;119:105328.
    PubMed     Abstract available


  231. DE FELICE F, Lei M, Oakley R, Lyons A, et al
    Risk stratified follow up for head and neck cancer patients - An evidence based proposal.
    Oral Oncol. 2021;119:105365.
    PubMed     Abstract available


  232. LIN MC, Leu YS, Chiang CJ, Ko JY, et al
    Adequate surgical margins for oral cancer: A Taiwan cancer registry national database analysis.
    Oral Oncol. 2021;119:105358.
    PubMed     Abstract available


  233. PENG Y, Xiao L, Rong H, Ou Z, et al
    Single-cell profiling of tumor-infiltrating TCF1/TCF7(+) T cells reveals a T lymphocyte subset associated with tertiary lymphoid structures/organs and a superior prognosis in oral cancer.
    Oral Oncol. 2021;119:105348.
    PubMed     Abstract available


  234. COSTANTINO A, De Virgilio A, Spriano G
    Is the current oropharyngeal cancer T classification adequate in the era of HPV and transoral robotic surgery?
    Oral Oncol. 2021 May 25:105359. doi: 10.1016/j.oraloncology.2021.105359.
    PubMed    


  235. DESIDERI I, Becherini C, Belgioia L, Merlotti A, et al
    Palliative radiotherapy in older adults with head and neck squamous cell carcinoma: A systematic review.
    Oral Oncol. 2021;119:105355.
    PubMed     Abstract available


  236. BERZENJI D, Sewnaik A, Keereweer S, Monserez DA, et al
    Dissemination patterns and chronology of distant metastasis affect survival of patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2021;119:105356.
    PubMed     Abstract available


  237. SCHOONBEEK RC, Bult FFS, Plaat BEC, Witjes MJH, et al
    Incidental findings during the diagnostic work-up in the head and neck cancer pathway: Effects on treatment delay and survival.
    Oral Oncol. 2021;118:105350.
    PubMed     Abstract available


  238. CHEN X, Li Y, Li X, Cao X, et al
    An interpretable machine learning prognostic system for locoregionally advanced nasopharyngeal carcinoma based on tumor burden features.
    Oral Oncol. 2021;118:105335.
    PubMed     Abstract available


  239. PATTERSON JM, Lu L, Watson LJ, Harding S, et al
    Trends in, and predictors of, swallowing and social eating outcomes in head and neck cancer survivors: A longitudinal analysis of head and neck 5000.
    Oral Oncol. 2021;118:105344.
    PubMed     Abstract available


  240. AL-QURAYSHI Z, Randolph GW, Kandil E
    Cost-effectiveness of computed tomography nodal scan in patients with papillary thyroid carcinoma.
    Oral Oncol. 2021;118:105326.
    PubMed     Abstract available


  241. VENTURA TMO, Santos PSS, Ribeiro NR, de Lima Leite A, et al
    Is there difference in the comparative and quantitative salivary proteome between stimulated and unstimulated saliva in head and neck cancer patients treated by radiotherapy?
    Oral Oncol. 2021 May 10:105315. doi: 10.1016/j.oraloncology.2021.105315.
    PubMed     Abstract available


  242. ZHOU L
    Concerns about human papillomavirus-associated oropharyngeal cancer detection methods.
    Oral Oncol. 2021;116:105143.
    PubMed    


  243. LI R, Wang Q, Yan L, Zhu Y, et al
    Radiotherapy versus partial laryngectomy in the management of early glottic cancer with anterior commissure involvement: A propensity score matched study with 256 patients.
    Oral Oncol. 2021;116:105230.
    PubMed     Abstract available


    April 2021
  244. DA SILVA LEONEL ACL, Ribeiro ILA, de Souza MLM, Kaminagakura E, et al
    COVID-19, changes in smoking behaviour, and head and neck cancer: Current data and future perspectives.
    Oral Oncol. 2021 Apr 30:105327. doi: 10.1016/j.oraloncology.2021.105327.
    PubMed    


  245. ZONG J, Liu Y, Liang Q, Xu H, et al
    Administration of oral maintenance chemotherapy for 1 year following definitive chemoradiotherapy may improve the survival of patients with stage N3 nasopharyngeal carcinoma.
    Oral Oncol. 2021;118:105313.
    PubMed     Abstract available


  246. SINHA NK, Kohli PS, Nagarajan K, Gochhait D, et al
    A nomogram for predicting the risk of neck node metastasis in oral cavity carcinoma using acoustic radiation force impulse imaging (ARFI).
    Oral Oncol. 2021;118:105311.
    PubMed     Abstract available


  247. CHEN JL, Wang Q, Huang LM, Xu YH, et al
    A rare case of Kimura disease with lumps on the cheek and behind the ear.
    Oral Oncol. 2021 Apr 28:105303. doi: 10.1016/j.oraloncology.2021.105303.
    PubMed    


  248. YVER CM, Shimunov D, Weinstein GS, Rajasekaran K, et al
    Oncologic and survival outcomes for resectable locally-advanced HPV-related oropharyngeal cancer treated with transoral robotic surgery.
    Oral Oncol. 2021;118:105307.
    PubMed     Abstract available


  249. LYNCH PT, Horani S, Lee R, Sumer BD, et al
    Effectiveness of physical activity interventions in improving objective and patient-reported outcomes in head and neck cancer survivors: A systematic review.
    Oral Oncol. 2021;117:105253.
    PubMed     Abstract available


  250. VALLINA C, Lopez-Pintor RM, Gonzalez-Serrano J, de Vicente JC, et al
    Genes involved in the epithelial-mesenchymal transition in oral cancer: A systematic review.
    Oral Oncol. 2021;117:105310.
    PubMed     Abstract available


  251. RAJASEKARAN K, Carey RM, Lin X, Seckar TD, et al
    The microbiome of HPV-positive tonsil squamous cell carcinoma and neck metastasis.
    Oral Oncol. 2021;117:105305.
    PubMed     Abstract available


  252. KREINBRINK PJ, Li J, Parajuli S, Wise-Draper TM, et al
    Pre-treatment absolute lymphocyte count predicts for improved survival in human papillomavirus (HPV)-driven oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2021;116:105245.
    PubMed     Abstract available


  253. DHAKAL R, Moeller BJ, Prabhu RS, Frenkel CH, et al
    Pattern of distant metastasis in oropharyngeal carcinoma - Do they differ by HPV status?
    Oral Oncol. 2021 Apr 18:105286. doi: 10.1016/j.oraloncology.2021.105286.
    PubMed    


  254. FANNY C, Sebastien L, Pascale G, Antoine N, et al
    Physician practice variation in head and neck cancer therapy: Results of a national survey.
    Oral Oncol. 2021;117:105293.
    PubMed     Abstract available


  255. MOUTAFI M, Economopoulou P, Rimm D, Psyrri A, et al
    PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.
    Oral Oncol. 2021;117:105292.
    PubMed     Abstract available


  256. XIANG ZF, Hu DF, Xiong HC, Li MY, et al
    Benefit of chemotherapy in stage III nasopharyngeal carcinoma: Analysis of the surveillance, epidemiology, and end results database.
    Oral Oncol. 2021;117:105284.
    PubMed     Abstract available


  257. KUMAR R, Dheeraj K
    Do ipsilateral lateralized squamous cell carcinomas of oral tongue with a depth of invasion (DOI) greater than 10 mm warrant a bilateral neck dissection to prevent future regional recurrences on contralateral side? A continuing conundrum.
    Oral Oncol. 2021 Apr 7:105285. doi: 10.1016/j.oraloncology.2021.105285.
    PubMed    


  258. SCHREIBER A, Mattavelli D, Accorona R, Rampinelli V, et al
    Endoscopic-assisted multi-portal compartmental resection of the masticatory space in oral cancer: Anatomical study and preliminary clinical experience.
    Oral Oncol. 2021;117:105269.
    PubMed     Abstract available


  259. SAKTHIVEL P, Raveendran S, Panda S, Singh CA, et al
    Synchronous primary neoplasia in patients with p16 positive oropharyngeal carcinoma: Does the 2nd cancer really matters?
    Oral Oncol. 2021;115:105113.
    PubMed    


  260. PRICE JM, West CM, Mistry HB, Betts G, et al
    Improved survival prediction for oropharyngeal cancer beyond TNMv8.
    Oral Oncol. 2021;115:105140.
    PubMed     Abstract available


    March 2021
  261. SWAIN M, Ghosh-Laskar S
    Stereotactic body radiotherapy (SBRT) for primary non-metastatic head and neck cancer: When less is enough.
    Oral Oncol. 2021;116:105265.
    PubMed     Abstract available


  262. IQBAL MS, Morgan D, West N, Paterson C, et al
    Hypofractionated chemoradiation (2.75 Gy per fraction) in Head and Neck Cancer: Extreme caution required.
    Oral Oncol. 2021 Mar 21:105261. doi: 10.1016/j.oraloncology.2021.105261.
    PubMed    


  263. CAO C, Gan X, He Y, Su Y, et al
    Diagnostic efficacy of PET-CT, CT, and MRI in preoperative assessment of mandibular invasion caused by head and neck cancer: A systematic review and meta-analysis.
    Oral Oncol. 2021;116:105264.
    PubMed     Abstract available


  264. PUCCI R, Cassoni A, Battisti A, Valentini V, et al
    Covid-19 pandemic and head and neck cancers, what should we expect?
    Oral Oncol. 2021 Mar 15:105263. doi: 10.1016/j.oraloncology.2021.105263.
    PubMed    


  265. TANI R, Ito N, Matsui K, Yamasaki S, et al
    MICA A5.1 homozygous genotype is associated with a risk for early-onset oral cancer.
    Oral Oncol. 2021;116:105256.
    PubMed     Abstract available


  266. DIANA G, Corica C
    Human Papilloma Virus vaccine and prevention of head and neck cancer, what is the current evidence?
    Oral Oncol. 2021;115:105168.
    PubMed     Abstract available


  267. KIM HAJ, Zeng PYF, Shaikh MH, Mundi N, et al
    All HPV-negative head and neck cancers are not the same: Analysis of the TCGA dataset reveals that anatomical sites have distinct mutation, transcriptome, hypoxia, and tumor microenvironment profiles.
    Oral Oncol. 2021;116:105260.
    PubMed     Abstract available


  268. ILHAN B, Guneri P, Wilder-Smith P
    The contribution of artificial intelligence to reducing the diagnostic delay in oral cancer.
    Oral Oncol. 2021;116:105254.
    PubMed     Abstract available


  269. MO Y, Zhang B, Pan Y, Qin Q, et al
    Impact of the weekday of the first intensity-modulated radiotherapy treatment on the survival outcomes of patients with nasopharyngeal carcinoma: A multicenter cohort study.
    Oral Oncol. 2021;116:105258.
    PubMed     Abstract available


  270. LAN R, Catherine JH, Chossegros C, Campana F, et al
    Temporal association between the introduction of public health programs and interest in oral cancers on the internet in the European Union.
    Oral Oncol. 2021 Mar 5:105250. doi: 10.1016/j.oraloncology.2021.105250.
    PubMed    


  271. CHUMPITAZ-CERRATE V, Chavez-Rimache L, Rodriguez-Flores A
    Challenges in the early diagnosis of oral cancer in rural populations in Peru during the COVID-19 pandemic.
    Oral Oncol. 2021 Mar 1:105251. doi: 10.1016/j.oraloncology.2021.105251.
    PubMed    


  272. DE ALMEIDA JR, Seungyeon Kim V, O'Sullivan B, Goldstein DP, et al
    Comparing unilateral vs. bilateral neck management in lateralized oropharyngeal cancer between surgical and radiation oncologists: An international practice pattern survey.
    Oral Oncol. 2021;114:105165.
    PubMed     Abstract available


  273. FERRARI M, Migliorati S, Tomasoni M, Crisafulli V, et al
    Sinonasal cancer encroaching the orbit: Ablation or preservation?
    Oral Oncol. 2021;114:105185.
    PubMed     Abstract available


  274. YANG K, Ahn YC, Nam H, Hong SD, et al
    Clinical features of post-radiation nasopharyngeal necrosis and their outcomes following surgical intervention in nasopharyngeal cancer patients.
    Oral Oncol. 2021;114:105180.
    PubMed     Abstract available


  275. HENG Y, Zhang D, Zhou L, Zhang M, et al
    Assessment and treatment strategies for occult contralateral lymph node metastasis in hypopharyngeal squamous cell carcinoma patients with ipsilateral node-positive necks.
    Oral Oncol. 2021;114:105183.
    PubMed     Abstract available


  276. CUI J, Wang D, Nie D, Liu W, et al
    Difference in tumor mutation burden between squamous cell carcinoma in the oral cavity and larynx.
    Oral Oncol. 2021;114:105142.
    PubMed     Abstract available


  277. OPPELT P, Ley JC, Worden F, Palka K, et al
    Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial.
    Oral Oncol. 2021;114:105164.
    PubMed     Abstract available


  278. GOOSMANN M, Chang S, Craig J
    Treating sinonasal crusting and infection after palatal and sinonasal cancer resection with topical antibiotic irrigations.
    Oral Oncol. 2021;114:105077.
    PubMed    


    February 2021
  279. AWAN MJ, Gittleman H, Barnholtz-Sloan J, Machtay M, et al
    Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522.
    Oral Oncol. 2021;116:105241.
    PubMed     Abstract available


  280. DEVARAJA K
    Erratum to "The surgical sequence of neck dissection and primary tumor excision could impact the locoregional recurrence rates in oral squamous cell carcinoma" [Oral Oncol. 110 (2020) 104809].
    Oral Oncol. 2021 Feb 24:105229. doi: 10.1016/j.oraloncology.2021.105229.
    PubMed    


  281. ZSCHAECK S, Weingartner J, Ghadjar P, Wust P, et al
    Fever range whole body hyperthermia for re-irradiation of head and neck squamous cell carcinomas: Final results of a prospective study.
    Oral Oncol. 2021;116:105240.
    PubMed     Abstract available


  282. LIN M, Yang Q, You R, Zou X, et al
    Metastatic characteristics associated with survival of synchronous metastatic nasopharyngeal carcinoma in non-epidemic areas.
    Oral Oncol. 2021;115:105200.
    PubMed     Abstract available


  283. NORTH LM, Harvey E, Vanle B, Shreenivas A, et al
    Frequent omission of radiation after flap reconstruction of head and neck cancer: Are we dooming patients to failure?
    Oral Oncol. 2021 Feb 18:105225. doi: 10.1016/j.oraloncology.2021.105225.
    PubMed    


  284. HUANG L, Zhang X, Bai Y, Chua KLM, et al
    Efficacy and safety of apatinib in recurrent/metastatic nasopharyngeal carcinoma: A pilot study.
    Oral Oncol. 2021;115:105222.
    PubMed     Abstract available


  285. FADEN DL, O'Boyle CJ, Lin DT, Deschler DG, et al
    Prospective assessment of multiple HPV-positive oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2021 Feb 15:105212. doi: 10.1016/j.oraloncology.2021.105212.
    PubMed    


  286. SANTOSO AMM, Jansen F, Lissenberg-Witte BI, Baatenburg de Jong RJ, et al
    Sleep quality trajectories from head and neck cancer diagnosis to six months after treatment.
    Oral Oncol. 2021;115:105211.
    PubMed     Abstract available


  287. LEON X, Orus C, Casasayas M, Neumann E, et al
    Trends in disease-specific survival of head and neck squamous cell carcinoma patients treated in a single institution over a 30-year period.
    Oral Oncol. 2021;115:105184.
    PubMed     Abstract available


  288. GALLO O, Locatello LG
    All that glitters is not gold: Clinical implications from the genetic analysis of head and neck cancer recurrences.
    Oral Oncol. 2021 Feb 10:105187. doi: 10.1016/j.oraloncology.2021.105187.
    PubMed    


  289. MA SJ, Iovoli AJ, Attwood K, Wooten KE, et al
    Association of significant financial burden with survival for head and neck cancer patients treated with radiation therapy.
    Oral Oncol. 2021;115:105196.
    PubMed     Abstract available


  290. ADKINS DR, Lin JC, Sacco A, Ley J, et al
    Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naive, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial.
    Oral Oncol. 2021;115:105192.
    PubMed     Abstract available


  291. MENEZES FDS, Fernandes GA, Antunes JLF, Villa LL, et al
    Global incidence trends in head and neck cancer for HPV-related and -unrelated subsites: A systematic review of population-based studies.
    Oral Oncol. 2021;115:105177.
    PubMed     Abstract available


  292. VIGANO A, De Felice F, Iacovelli NA, Alterio D, et al
    M. D. Anderson symptom inventory head neck (MDASI-HN) questionnaire: Italian language psychometric validation in head and neck cancer patients treated with radiotherapy +/- systemic therapy - A study of the Italian Association of Radiotherapy and Clin
    Oral Oncol. 2021;115:105189.
    PubMed     Abstract available


  293. OH LJ, Satgunaseelan L, Asher R, Veness M, et al
    Young age is not a predictor of disease specific survival in oral cancer: A multi-institutional study.
    Oral Oncol. 2021;115:105162.
    PubMed     Abstract available


  294. ADKINS D, Ley J, Atiq O, Powell S, et al
    Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial.
    Oral Oncol. 2021;115:105173.
    PubMed     Abstract available


  295. LEE SJ, Kim YS, Kay CS, Kim M, et al
    The effect of adjuvant chemotherapy and early tumor regression on the outcome of nasopharyngeal cancer patients treated with concurrent chemoradiotherapy.
    Oral Oncol. 2021;113:105130.
    PubMed     Abstract available


  296. CARNEVALE C, Ortiz-Gonzalez I, Ortiz-Gonzalez A, Bodi-Blanes L, et al
    Early T1-T2 stage p16+ oropharyngeal tumours. Role of upfront transoral robotic surgery in de-escalation treatment strategies. A review of the current literature.
    Oral Oncol. 2021;113:105111.
    PubMed     Abstract available


  297. HEFT NEAL ME, Gao RW, Brennan JR, Haring CT, et al
    Functional outcomes and tracheostomy dependence following salvage oropharyngeal surgery.
    Oral Oncol. 2021;113:105034.
    PubMed    


    January 2021
  298. THADURI A, Chadha L, Poonia DR, Rajkumar KS, et al
    Oral cancer screening - A delphic horizon in India.
    Oral Oncol. 2021 Jan 26:105174. doi: 10.1016/j.oraloncology.2020.105174.
    PubMed    


  299. MA HH, Chen DS, Li S, Xiao MZ, et al
    The value and inadequacy of tumor mutation burden on efficacy of immune checkpoint inhibitors in head and neck cancers.
    Oral Oncol. 2021 Jan 26:105179. doi: 10.1016/j.oraloncology.2021.105179.
    PubMed    


  300. JELINEK MJ, Foster NR, Zoroufy AJ, Schwartz GK, et al
    A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101.
    Oral Oncol. 2021;114:105171.
    PubMed     Abstract available


  301. CHAN SK, Chan SY, Tong CC, Lam KO, et al
    Comparison of efficacy and safety of three induction chemotherapy regimens with gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) for locoregionally advanced previously untreated nasopharyngeal carc
    Oral Oncol. 2021;114:105158.
    PubMed     Abstract available


  302. PILAR A, Yu E, Su J, O'Sullivan B, et al
    Prognostic value of clinical and radiologic extranodal extension and their role in the 8th edition TNM cN classification for HPV-negative oropharyngeal carcinoma.
    Oral Oncol. 2021;114:105167.
    PubMed     Abstract available


  303. HOWLETT J, Hamilton S, Ye A, Jewett D, et al
    Treatment and outcomes of nasopharyngeal carcinoma in a unique non-endemic population.
    Oral Oncol. 2021;114:105182.
    PubMed     Abstract available


  304. MARTELLI AJ, Machado RA, Pereira WM, Silveira DMM, et al
    Impact of the COVID-19 pandemic in the head and neck cancer treatment in the Brazil.
    Oral Oncol. 2021 Jan 18:105148. doi: 10.1016/j.oraloncology.2020.105148.
    PubMed    


  305. DEVARAJA K
    De-escalation of aggressive adjuvant therapy for limited extranodal extension in head and neck cancer.
    Oral Oncol. 2021 Jan 18:105161. doi: 10.1016/j.oraloncology.2020.105161.
    PubMed    


  306. BHATTASALI O, Torres FA, Kang HK, Thompson LDR, et al
    Prognostic impact of retropharyngeal lymphadenopathy in early-stage HPV-associated oropharyngeal cancer: Implications for staging optimization.
    Oral Oncol. 2021;114:105147.
    PubMed    


  307. VARELA-CENTELLES P, Seoane J, Bilbao A, Seoane-Romero J, et al
    Covid-19 pandemic: A new contributing factor to diagnostic and treatment delay in oral cancer patients.
    Oral Oncol. 2021 Jan 15:105176. doi: 10.1016/j.oraloncology.2020.105176.
    PubMed    


  308. JOHNSON D, Ma BBY
    Targeting the PD-1/ PD-L1 interaction in nasopharyngeal carcinoma.
    Oral Oncol. 2021;113:105127.
    PubMed     Abstract available


  309. TREVISIOL C, Gion M, Vaona A, Fabricio ASC, et al
    The appropriate use of circulating EBV-DNA in nasopharyngeal carcinoma: Comprehensive clinical practice guidelines evaluation.
    Oral Oncol. 2021;114:105128.
    PubMed     Abstract available


  310. EMMETT SE, Stark MS, Pandeya N, Panizza B, et al
    MicroRNA expression is associated with human papillomavirus status and prognosis in mucosal head and neck squamous cell carcinomas.
    Oral Oncol. 2021;113:105136.
    PubMed     Abstract available


  311. SHER DJ, Yan J, Day AT, Khan S, et al
    Comparative cost analysis between definitive radiotherapy and transoral surgery for oropharyngeal squamous cell carcinoma: A SEER-Medicare analysis.
    Oral Oncol. 2021;112:105029.
    PubMed     Abstract available


  312. WINDON MJ, Le D, D'Souza G, Bigelow E, et al
    Treatment decision-making among patients with oropharyngeal squamous cell cancer: A qualitative study.
    Oral Oncol. 2021;112:105044.
    PubMed     Abstract available


  313. FLUKES S, Lohia S, Barker CA, Cracchiolo JR, et al
    Are our patients doing better? A single institution experience of an evolving management paradigm for sinonasal mucosal melanoma.
    Oral Oncol. 2021;112:105006.
    PubMed    


    December 2020
  314. LORINI L, Merlano M, Licitra L, Ravanelli M, et al
    Brain metastasis in head and neck squamous cell carcinoma after immune check point inhibitors treatment.
    Oral Oncol. 2020 Dec 31:105138. doi: 10.1016/j.oraloncology.2020.105138.
    PubMed    


  315. VIPPARTHI K, Patel AK, Ghosh S, Das S, et al
    Two novel cell culture models of buccal mucosal oral cancer from patients with no risk-habits of tobacco smoking or chewing.
    Oral Oncol. 2020;113:105131.
    PubMed     Abstract available


  316. PELLINI R, Campo F, Sergi D, Cappuzzo F, et al
    Role of Pembrolizumab in recurrent or metastatic head and neck carcinoma.
    Oral Oncol. 2020 Dec 29:105133. doi: 10.1016/j.oraloncology.2020.105133.
    PubMed    


  317. ALMANGUSH A, Makitie AA, Leivo I
    Back to basics: Hematoxylin and eosin staining is the principal tool for histopathological risk assessment of oral cancer.
    Oral Oncol. 2020 Dec 29:105134. doi: 10.1016/j.oraloncology.2020.105134.
    PubMed    


  318. MATSUO M, Yasumatsu R, Masuda M, Toh S, et al
    Drug-induced interstitial lung disease in recurrent and/or metastatic head and neck cancer patients treated with cetuximab and/or nivolumab.
    Oral Oncol. 2020;113:105129.
    PubMed     Abstract available


  319. CHRISTOPHERSON KM, Moreno AC, Elgohari B, Gross N, et al
    Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation.
    Oral Oncol. 2020;113:105125.
    PubMed     Abstract available


  320. SUBRAMANIAM N, Clark JR, Goldstein D, de Almeida J, et al
    Geographical heterogeneity in the American Joint committee on Cancer oral cancer staging and prognostic implications.
    Oral Oncol. 2020;113:105122.
    PubMed     Abstract available


  321. NOEL CW, Sutradhar R, Li Q, Forner D, et al
    Chinese and South Asian ethnicity, immigration status and head and neck cancer outcomes: A population based study.
    Oral Oncol. 2020;113:105118.
    PubMed     Abstract available


    November 2020
  322. KOBAYASHI K, Yoshimoto S, Ando M, Matsumoto F, et al
    Full-coverage TP53 deep sequencing of recurrent head and neck squamous cell carcinoma facilitates prognostic assessment after recurrence.
    Oral Oncol. 2020;113:105091.
    PubMed     Abstract available


  323. MAZUL AL, Naik AN, Zhan KY, Stepan KO, et al
    Gender and race interact to influence survival disparities in head and neck cancer.
    Oral Oncol. 2020;112:105093.
    PubMed     Abstract available


  324. MASHIANA SS, Navale P, Khandakar B, Sobotka S, et al
    Human papillomavirus genotype distribution in head and neck cancer: Informing developing strategies for cancer prevention, diagnosis, treatment and surveillance.
    Oral Oncol. 2020;113:105109.
    PubMed     Abstract available


  325. ROY D, Patel A, Goswami G, Samantaray S, et al
    Role of Onco rehabilitation in head and neck cancer.
    Oral Oncol. 2020 Nov 19:105015. doi: 10.1016/j.oraloncology.2020.105015.
    PubMed    


  326. KHAN SA, Burke M, Zhu F, Yang DH, et al
    Survivin expression and impact on head and neck cancer outcomes.
    Oral Oncol. 2020;112:105049.
    PubMed     Abstract available


  327. ZHAO XT, Zhu Y, Zhou JF, Gao YJ, et al
    Development of a novel 7 immune-related genes prognostic model for oral cancer: A study based on TCGA database.
    Oral Oncol. 2020;112:105088.
    PubMed     Abstract available


  328. CHAKRABARTI D, Akhtar N, Qayoom S, Rajan S, et al
    Optimising elective neck dissection for early oral cancers.
    Oral Oncol. 2020 Nov 13:105090. doi: 10.1016/j.oraloncology.2020.105090.
    PubMed    


  329. WIJETUNGA NA, Yu Y, Morris LG, Lee N, et al
    The head and neck cancer genome in the era of immunotherapy.
    Oral Oncol. 2020;112:105040.
    PubMed     Abstract available


  330. ZHAI TT, Wesseling F, Langendijk JA, Shi Z, et al
    External validation of nodal failure prediction models including radiomics in head and neck cancer.
    Oral Oncol. 2020;112:105083.
    PubMed     Abstract available


  331. REGO-LORCA D, Burgos-Blasco B, Hernandez-Garcia E, Domingo-Gordo B, et al
    Abducens palsy as first manifestation of a nasopharyngeal carcinoma.
    Oral Oncol. 2020 Nov 10:105079. doi: 10.1016/j.oraloncology.2020.105079.
    PubMed    


  332. LIU AK, Wu J, Berthelet E, Lalani N, et al
    Clinical features of head and neck cancer patients with brain metastases: A retrospective study of 88 cases.
    Oral Oncol. 2020;112:105086.
    PubMed     Abstract available


  333. CHO JH, Lim YC
    Prognostic impact of regulatory T cell in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2020;112:105084.
    PubMed     Abstract available


  334. HANNA GJ, Rettig EM, Park JC, Varvares MA, et al
    Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19.
    Oral Oncol. 2020;112:105087.
    PubMed     Abstract available


  335. AMPIL F, Cuellar H, Nathan CA, Smith D, et al
    Recurrent head and neck cancers in the skull base, stereotactic radiosurgery palliation, and risk prognosticators.
    Oral Oncol. 2020 Nov 3:105005. doi: 10.1016/j.oraloncology.2020.105005.
    PubMed    


  336. SAKTHIVEL P, Samy K, Panda S, Amit Singh C, et al
    14 "S" in head and neck cancers.
    Oral Oncol. 2020;112:105070.
    PubMed    


    October 2020
  337. AMPIL FL, Nathan CA, Asarkar A
    Long-term survival in patients with intermediate-risk head and neck cancer treated with adjuvant radiotherapy.
    Oral Oncol. 2020 Oct 30:105071. doi: 10.1016/j.oraloncology.2020.105071.
    PubMed    


  338. PANDOLFINI M, Di Stadio A, Brenner MJ, Pichi B, et al
    Airway obstruction from tracheostomy balloon cuff herniation during oral cancer asportation. Emergency successfully managed and lessons learnt from device malfunction.
    Oral Oncol. 2020 Oct 29:105048. doi: 10.1016/j.oraloncology.2020.105048.
    PubMed     Abstract available


  339. SAIDAK Z, Galmiche A, Lottin M, Montes L, et al
    The coagulome of Head and Neck Squamous Cell Carcinoma.
    Oral Oncol. 2020 Oct 28:105068. doi: 10.1016/j.oraloncology.2020.105068.
    PubMed    


  340. FLEMING CW, Ward MC, Woody NM, Joshi NP, et al
    Identifying an oligometastatic phenotype in HPV-associated oropharyngeal squamous cell cancer: Implications for clinical trial design.
    Oral Oncol. 2020;112:105046.
    PubMed     Abstract available


  341. MILLIET F, Bozec A, Schiappa R, Viotti J, et al
    Synchronous primary neoplasia in patients with oropharyngeal cancer: Impact of tumor HPV status. A GETTEC multicentric study.
    Oral Oncol. 2020;112:105041.
    PubMed     Abstract available


  342. IMADUDDIN M, Sultania M, Vigneshwaran B, Muduly DK, et al
    Metronomic therapy using Methotrexate and Celecoxib: A Boon for Oral Cancer patients during COVID-19 Pandemic.
    Oral Oncol. 2020 Oct 24:105069. doi: 10.1016/j.oraloncology.2020.105069.
    PubMed    


  343. MORIKAWA T, Shibahara T, Takano M, Iwamoto M, et al
    Countermeasure and opportunistic screening systems for oral cancer.
    Oral Oncol. 2020;112:105047.
    PubMed     Abstract available


  344. GUPTA T, Ghosh-Laskar S, Agarwal JP
    Resource-sparing curative-intent hypofractionated-accelerated radiotherapy in head and neck cancer: More relevant than ever before in the COVID era.
    Oral Oncol. 2020;111:105045.
    PubMed     Abstract available


  345. LEK SM, Li K, Tan QX, Shannon NB, et al
    Pairing a prognostic target with potential therapeutic strategy for head and neck cancer.
    Oral Oncol. 2020;111:105035.
    PubMed     Abstract available


  346. FERRARI M, Paderno A, Giannini L, Cazzador D, et al
    COVID-19 screening protocols for preoperative assessment of head and neck cancer patients candidate for elective surgery in the midst of the pandemic: A narrative review with comparison between two Italian institutions.
    Oral Oncol. 2020;112:105043.
    PubMed     Abstract available


  347. PARK JC, Durbeck J, Clark JR, Faden DL, et al
    Treatment sequence of cetuximab and immune checkpoint inhibitor in head and neck squamous cell carcinoma differentially affects outcomes.
    Oral Oncol. 2020;111:105024.
    PubMed     Abstract available


  348. DE VRIES J, Bras L, Sidorenkov G, Festen S, et al
    Frailty is associated with decline in health-related quality of life of patients treated for head and neck cancer.
    Oral Oncol. 2020;111:105020.
    PubMed     Abstract available


  349. CONTRERA KJ, Smile TD, Mahomva C, Wei W, et al
    Locoregional and distant recurrence for HPV-associated oropharyngeal cancer using AJCC 8 staging.
    Oral Oncol. 2020;111:105030.
    PubMed     Abstract available


  350. HUANG S, Piao Y, Cao C, Chen J, et al
    A prospective randomized controlled trial on the value of prophylactic oral nutritional supplementation in locally advanced nasopharyngeal carcinoma patients receiving chemo-radiotherapy.
    Oral Oncol. 2020;111:105025.
    PubMed     Abstract available


  351. SUBRAMANIAM N, Dhar SK, Rao R, Prasad K, et al
    Novel tyrosine metabolites in the transcriptomic profiling of smokeless tobacco related oral cancer and their potential implications.
    Oral Oncol. 2020 Oct 1:105027. doi: 10.1016/j.oraloncology.2020.105027.
    PubMed    


  352. CUSTODIO M, Biddle A, Tavassoli M
    Portrait of a CAF: The story of cancer-associated fibroblasts in head and neck cancer.
    Oral Oncol. 2020;110:104972.
    PubMed     Abstract available


    September 2020
  353. CHOW JCH, Tam AHP, Cheung KM, Lee VHF, et al
    Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma: A territory-wide study by HKNPCSG.
    Oral Oncol. 2020;111:105012.
    PubMed     Abstract available


  354. ECONOMOPOULOU P, Kotsantis I, Papaxoinis G, Gavrielatou N, et al
    Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
    Oral Oncol. 2020;111:105013.
    PubMed     Abstract available


  355. RAPADO-GONZALEZ O, Muinelo-Romay L, Suarez-Cunqueiro MM
    Letter to the editor: "Liquid biopsy based on saliva cell-free DNA as a potential biomarker for head and neck cancer".
    Oral Oncol. 2020 Sep 21:105016. doi: 10.1016/j.oraloncology.2020.105016.
    PubMed    


  356. YETE S, Saranath D
    MicroRNAs in oral cancer: Biomarkers with clinical potential.
    Oral Oncol. 2020;110:105002.
    PubMed     Abstract available


  357. MARTIN M, Sautois B
    Early onset of head and neck squamous-cell carcinoma and fatal toxicity with concurrent chemoradiotherapy in a patient compound heterozygote for FANCA gene.
    Oral Oncol. 2020 Sep 1:104989. doi: 10.1016/j.oraloncology.2020.104989.
    PubMed    


    August 2020
  358. FAKHRY C, Fung N, Tewari SR, D'Souza G, et al
    Unique role of HPV16 in predicting oropharyngeal cancer risk more than other oncogenic oral HPV infections.
    Oral Oncol. 2020 Aug 29:104981. doi: 10.1016/j.oraloncology.2020.104981.
    PubMed    


  359. CHEN TC, Wu CT, Wang CP, Lou PJ, et al
    The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer.
    Oral Oncol. 2020;111:104945.
    PubMed     Abstract available


  360. WANG J, Lian CL, Zheng H, Lin LE, et al
    Cognitive dysfunction in patients with nasopharyngeal carcinoma after induction chemotherapy.
    Oral Oncol. 2020;111:104921.
    PubMed     Abstract available


  361. DENARO N, Merlotti AM, Merlano MC, Russi E, et al
    Coronavirus disease 19 (COVID-19) during chemoradiation for locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC).
    Oral Oncol. 2020;107:104801.
    PubMed    


    July 2020
  362. ZENG YY, Xiang ZZ, He T, Liu F, et al
    The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2020;111:104924.
    PubMed     Abstract available


  363. WANG Q, Xu G, Xia Y, Zuo J, et al
    Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2020;111:104925.
    PubMed     Abstract available


  364. LI W, Lu H, Liu J, Liu Q, et al
    A novel nomogram to predict survival in patients with recurrent nasopharyngeal carcinoma after salvage endoscopic surgery.
    Oral Oncol. 2020;111:104922.
    PubMed     Abstract available


  365. HSU AC, Kokot NC, Eisenberg BL, Thomas JS, et al
    Complete response with talimogene laherparepvec in recurrent melanoma of the ear: A case report.
    Oral Oncol. 2020 Jul 11:104899. doi: 10.1016/j.oraloncology.2020.104899.
    PubMed     Abstract available


  366. MATOS LL, Pinheiro RA, Kowalski LP
    Depth of invasion applied to oropharynx does not improve prognosis discrimination according to AJCC stage groups for oral cancer.
    Oral Oncol. 2020 Jul 9:104890. doi: 10.1016/j.oraloncology.2020.104890.
    PubMed    


  367. BRCIC I, Gallob M, Schwantzer G, Zrnc T, et al
    Concordance of tumor infiltrating lymphocytes, PD-L1 and p16 expression in small biopsies, resection and lymph node metastases of oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2020;106:104719.
    PubMed     Abstract available


  368. COHEN ER, Reis IM, Gomez-Fernandez C, Smith D, et al
    CD44 and associated markers in oral rinses and tissues from oral and oropharyngeal cancer patients.
    Oral Oncol. 2020;106:104720.
    PubMed     Abstract available


  369. KISHIMOTO Y, Tateya I, Funakoshi M, Miyamoto SI, et al
    Endoscopic laryngopharyngeal surgery for hypopharyngeal lesions.
    Oral Oncol. 2020;106:104655.
    PubMed     Abstract available


  370. SEKARUTAMI SM, Gondhowiardjo S, Yuliasti R, Syarifah L, et al
    Survival of nasopharyngeal cancer in national referral hospital of Indonesia: A study on radiotherapy patients.
    Oral Oncol. 2020;106:104707.
    PubMed     Abstract available


  371. FERRARI M, Ioppi A, Schreiber A, Gualtieri T, et al
    Malignant tumors of the maxillary sinus: Prognostic impact of neurovascular invasion in a series of 138 patients.
    Oral Oncol. 2020;106:104672.
    PubMed     Abstract available


    June 2020
  372. KREIMER AR, Chaturvedi AK, Alemany L, Anantharaman D, et al
    Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI.
    Oral Oncol. 2020;108:104736.
    PubMed     Abstract available


  373. IQBAL MS, Warner L, Paleri V, Kovarik J, et al
    De-intensification of treatment in human papilloma virus related oropharyngeal carcinoma: Patient choice still matters for de-escalation and for the COVID era.
    Oral Oncol. 2020;105:104768.
    PubMed    


  374. SASAKI CT, Hajek M, Doukas SG, Vageli DP, et al
    The role of bile reflux and its related NF-kappaB activated pathway in progression of hypopharyngeal squamous cell cancer.
    Oral Oncol. 2020;105:104668.
    PubMed     Abstract available


  375. BIGELOW EO, Seiwert TY, Fakhry C
    Deintensification of treatment for human papillomavirus-related oropharyngeal cancer: Current state and future directions.
    Oral Oncol. 2020;105:104652.
    PubMed     Abstract available


  376. JANK BJ, Kadletz L, Dunkler D, Haas M, et al
    Epithelial stem cell marker LGR6 expression identifies a low-risk subgroup in human papillomavirus positive oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2020;105:104657.
    PubMed     Abstract available


    May 2020
  377. JOO YH, Cho KJ, Kim GJ, Kim MS, et al
    Prognostic impact of resection margin involvement in surgically managed HPV-positive tonsil cancer.
    Oral Oncol. 2020;108:104806.
    PubMed     Abstract available


  378. KYLMA AK, Jouhi L, Mohamed H, Randen-Brady R, et al
    In HPV-negative oropharyngeal squamous cell carcinoma, elevated toll-like receptor 2 immunoexpression may increase the risk of disease-specific mortality.
    Oral Oncol. 2020;107:104778.
    PubMed     Abstract available


  379. MANNELLI G, Gazzini L, Comini LV, Parrinello G, et al
    Double free flaps in oral cavity and oropharynx reconstruction: Systematic review, indications and limits.
    Oral Oncol. 2020;104:104637.
    PubMed     Abstract available


  380. CHOW VLY, Chan JYW, Cheng IKY, Chan KMK, et al
    Swallowing disorders following free jejunal flap reconstruction of circumferential pharyngeal defect: Does Botox help?
    Oral Oncol. 2020;104:104612.
    PubMed     Abstract available


    April 2020
  381. MOLONY P, Werner R, Martin C, Callanan D, et al
    The role of tumour morphology in assigning HPV status in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2020;105:104670.
    PubMed     Abstract available


  382. PATEL RR, Ludmir EB, Augustyn A, Zaorsky NG, et al
    De-intensification of therapy in human papillomavirus associated oropharyngeal cancer: A systematic review of prospective trials.
    Oral Oncol. 2020;103:104608.
    PubMed     Abstract available


  383. DE VIRGILIO A, Costantino A, Mercante G, Di Maio P, et al
    Trans-oral robotic surgery in the management of parapharyngeal space tumors: A systematic review.
    Oral Oncol. 2020;103:104581.
    PubMed     Abstract available


  384. CANAVAN JF, Harr BA, Bodmann JW, Reddy CA, et al
    Impact of routine surveillance imaging on detecting recurrence in human papillomavirus associated oropharyngeal cancer.
    Oral Oncol. 2020;103:104585.
    PubMed     Abstract available


  385. FARLOW JL, Rosko AJ, Spector ME
    Treatment of end-stage pharyngeal strictures after laryngectomy with fasciocutaneous microvascular reconstruction.
    Oral Oncol. 2020;103:104556.
    PubMed     Abstract available


  386. CABEZAS-CAMARERO S, Perez-Alfayate R, Puebla F, Cabrera-Martin MN, et al
    Increased clinical and plasma EBV DNA responses to platinum-gemcitabine after nivolumab in patients with heavily platinum-pretreated nasopharyngeal cancer.
    Oral Oncol. 2020;103:104527.
    PubMed    


    March 2020
  387. MAZUL AL, Colditz GA, Zevallos JP
    Factors associated with HPV testing in oropharyngeal cancer in the National Cancer Data Base from 2013 to 2015.
    Oral Oncol. 2020;104:104609.
    PubMed     Abstract available


  388. SANDULACHE VC, Lei YL, Heasley LE, Chang M, et al
    Innovations in risk-stratification and treatment of Veterans with oropharynx cancer; roadmap of the 2019 Field Based Meeting.
    Oral Oncol. 2020;102:104440.
    PubMed    


    February 2020
  389. YIN X, Shan C, Wang J, Zhang H, et al
    Factors associated with the quality of life for hospitalized patients with HPV-associated oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2020;103:104590.
    PubMed     Abstract available


  390. FAKHRY C, Waterboer T, Westra WH, Rooper LM, et al
    Distinct biomarker and behavioral profiles of human papillomavirus-related oropharynx cancer patients by age.
    Oral Oncol. 2020;101:104522.
    PubMed     Abstract available


  391. WANG Z, Qu Y, Wang K, Wu R, et al
    The value of preoperative radiotherapy in the treatment of locally advanced nasal cavity and paranasal sinus squamous cell carcinoma: A single institutional experience.
    Oral Oncol. 2020;101:104512.
    PubMed     Abstract available


  392. CHARGI N, Bril SI, Swartz JE, Wegner I, et al
    Skeletal muscle mass is an imaging biomarker for decreased survival in patients with oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2020;101:104519.
    PubMed     Abstract available


  393. SATO K, Ono T, Sato F, Kawahara A, et al
    Different responses to nivolumab therapy between primary and metastatic tumors in a patient with recurrent hypopharyngeal squamous cell carcinoma.
    Oral Oncol. 2020;101:104366.
    PubMed     Abstract available


    December 2019
  394. YOUNG RJ, Bressel M, Porceddu S, Cernelc J, et al
    Validation and characterisation of prognostically significant PD-L1(+) immune cells in HPV+ oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2019;101:104516.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Otorhinolaryngology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: